IP Verse

Use Of Riluzole Prodrugs To Treat Ataxias - EP3706739

The patent EP3706739 was granted to Biohaven Pharmaceutical Holding on Oct 16, 2024. The application was originally filed on Nov 11, 2018 under application number EP18876779A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3706739

BIOHAVEN PHARMACEUTICAL HOLDING
Application Number
EP18876779A
Filing Date
Nov 11, 2018
Status
Granted And Under Opposition
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBJul 2, 2025ADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2016US19773-
DESCRIPTIONWO2016US19787-
DESCRIPTIONUS5631023
DESCRIPTIONUS5837287
DESCRIPTIONUS6149938
DESCRIPTIONUS6212791
DESCRIPTIONUS6284270
DESCRIPTIONUS6316029
DESCRIPTIONUS6465010
DESCRIPTIONUS6471992
DESCRIPTIONUS6509040
DESCRIPTIONUS6814978
DESCRIPTIONUS6908626
DESCRIPTIONUS6982251
DESCRIPTIONUS7282217
DESCRIPTIONUS7425341
DESCRIPTIONUS7939105
DESCRIPTIONUS7993674
DESCRIPTIONUS8048449
DESCRIPTIONUS8127516
DESCRIPTIONUS8158152
DESCRIPTIONUS8221480
DESCRIPTIONUS8256233
DESCRIPTIONUS8313768
DESCRIPTIONWO2016140879
INTERNATIONAL-SEARCH-REPORTUS2014371208
INTERNATIONAL-SEARCH-REPORTWO2016140878
OPPOSITIONWO2016140879
SEARCHWO2016140879

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Anonymous, "Analysis of 96 Week, Long-Term Open Label Extension Phase of Study BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia", Neurology, 96 (15 Supplement), (20210417), pages 1 - 7, URL: https://n.neurology.org/content/96/15_Supplement/2837, (20230914), XP093082171-
EXAMINATION- Romano Silvia ET AL, "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial - Supplementary webappendix", The Lancet Neurology, AMSTERDAM, NL, vol. 14, no. 10, doi:10.1016/S1474-4422(15)00201-X, ISSN 1474-4422, (20151001), pages 985 - 991, URL: https://ars.els-cdn.com/content/image/1-s2.0-S147444221500201X-mmc1.pdf, XP093081817
OPPOSITION- Romano Silvia, Coarelli Giulia, Marcotulli Christian, Leonardi Luca, Piccolo Francesca, Spadaro Maria, Frontali Marina, Ferraldeschi Michela, Vulpiani Maria Chiara, Ponzelli Federica, Salvetti Marco, Orzi Francesco, Petrucci Antonio, Vanacore Nicola, Casali Carlo, Ristori Giovanni, "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial - Supplementary webappendix", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20151001), vol. 14, no. 10, doi:10.1016/S1474-4422(15)00201-X, ISSN 1474-4422, pages 985 - 991, XP093081817
OPPOSITION- Romano Silvia, Coarelli Giulia, Marcotulli Christian, Leonardi Luca, Piccolo Francesca, Spadaro Maria, Frontali Marina, Ferraldeschi Michela, Vulpiani Maria Chiara, Ponzelli Federica, Salvetti Marco, Orzi Francesco, Petrucci Antonio, Vanacore Nicola, Casali Carlo, Ristori Giovanni, "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial", The Lancet Neurology, doi:10.1016/S1474-4422(15)00201-X, pages 985 - 991, The Lancet Neurology, (20210618), XP055815706
OPPOSITION- Manto Mario-Ubaldo, "The wide spectrum of spinocerebellar ataxias (SCAs)", CEREBELLUM, TAYLOR AND FRANCIS,, GB, GB , (20050101), vol. 4, no. 1, doi:10.1080/14734220510007914, ISSN 1473-4222, pages 2 - 6, XP093295740
OPPOSITION- Ristori G., Romano S., Visconti A., Cannoni S., Spadaro M., Frontali M., Pontieri F. E., Vanacore N., Salvetti M., "Riluzole in cerebellar ataxia: A randomized, double-blind, placebo-controlled pilot trial", Neurology, Lippincott Williams & Wilkins, (20100309), vol. 74, no. 10, doi:10.1212/WNL.0b013e3181d31e23, ISSN 0028-3878, pages 839 - 845, XP093021905
SEARCH- Romano Silvia ET AL, "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial", The Lancet Neurology, doi:10.1016/S1474-4422(15)00201-X, (20150826), pages 985 - 991, URL: https://www.sciencedirect.com/science/article/pii/S147444221500201X?via%3Dihub, (20210618), XP055815706 [YD] 1-9 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents